Skip to content
Bored Studies
RecruitingPhase 3

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

Eli Lilly and Company · NCT07794579

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 3
Target enrollment
2001
US sites recruiting
69
Study start
August 26, 2026
Record last updated
October 8, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This study will evaluate the efficacy and safety of orforglipron in participants with overweight and assess whether it helps reduce the future risk of obesity-related conditions, including type 2 diabetes, hypertension, and dyslipidemia, and progression to class 1 obesity.

Being studied: Orforglipron; Placebo

Conditions: Overweight; Prediabetic State; Prehypertension; Obesity, Abdominal

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Have an increased waist-to-height ratio of ≥0.5
  • Have at least one pre-obesity-related complication (prediabetes, prehypertension, predyslipidemia)
  • Have at least one unsuccessful attempt to reduce body weight based on diet and exercise
  • Have a BMI greater than or equal to 25 to less than or equal to 29.9 kg/m2 or equivalent-/region-specific overweight thresholds

Exclusion Criteria

  • Have type 1 diabetes, type 2 diabetes, or any other type of diabetes
  • Do not have a stable body weight within 90 days before screening
  • Have a documented obesity diagnosis or self-reported history of BMI ≥30 kg/m² (or an equivalent region-specific threshold)
  • Have taken medications for weight loss, including over-the counter medications or alternative therapies, within 180 days prior to screening
  • Have a prior or planned surgical treatment or procedure for obesity
  • Have hypertension or history of hypertension
  • Have dyslipidemia or history of dyslipidemia

Recruiting US locations

  • Pinnacle Research Group, LLC

    Anniston, AL 36207

    Site contact: 256-236-0055

  • Central Research Associates

    Birmingham, AL 35205

    Site contact: 205-327-1077

  • Cahaba Research - Pelham

    Pelham, AL 35124

    Site contact: 205-408-4134

  • Care Access - 801 South Power Road, Mesa

    Mesa, AZ 85206

    Site contact: 877-791-0656

  • Synexus Clinical Research US, Inc./Orange Grove Family Practice

    Tucson, AZ 85741

    Site contact: 520-333-4515

  • Orange County Research Center

    Lake Forest, CA 92630

    Site contact: 714-550-9990

  • Healthy Brain Clinic

    Long Beach, CA 90804

    Site contact: 562-606-5999

  • Los Angeles Institute for Metabolic Research

    Los Angeles, CA 90015

    Site contact: 213-373-8380

  • Desert Oasis Healthcare Medical Group

    Palm Springs, CA 92262

    Site contact: 760-320-9505

  • Artemis Institute for Clinical Research

    Riverside, CA 92503

    Site contact: 951-374-1190

  • Riverside Clinical

    Riverside, CA 92506

    Site contact: 951-374-8000

  • Headlands Research- Sacramento

    Sacramento, CA 95821

    Site contact: 916-434-8230

  • Norcal Endocrinology & Internal Medicine

    San Ramon, CA 94583

    Site contact: 925-552-5280

  • Diablo Clinical Research, Inc.

    Walnut Creek, CA 94598

    Site contact: 925-930-7267

  • Chase Medical Research, LLC

    Waterbury, CT 06708

    Site contact: 203-419-4420

  • Excel Medical Clinical Trials

    Boca Raton, FL 33434

    Site contact: 305-631-6704

  • Flourish Research Acquisition, LLC dba Flourish Research - North Miami

    Miami, FL 33138

    Site contact: 786-772-0411

  • New Age Medical Research Corporation

    Miami, FL 33186

    Site contact: 305-596-9901

  • Renstar Medical Research

    Ocala, FL 34471

    Site contact: 352-629-5800

  • Headlands Research Orlando

    Orlando, FL 32803

    Site contact: 407-705-3471

  • Oviedo Medical Research

    Oviedo, FL 32765

    Site contact: 407-977-2705

  • Care Access - St. Petersburg

    St. Petersburg, FL 33710

    Site contact: 877-791-0656

  • Precision Clinical Research

    Sunrise, FL 33351

    Site contact: Jeffrey Schneider

  • SKY Clinical Research Network Group-Brown

    Atlanta, GA 30331

    Site contact: 888-659-4363

  • HOPE Clinical Research & Wellness

    Conyers, GA 30094

    Site contact: 770-679-5591

  • Care Access - Dalton Walmart

    Dalton, GA 30720

    Site contact: 877-791-0656

  • Care Access - Decatur

    Decatur, GA 30030

    Site contact: 678-470-4394

  • Family First Medical Center

    Idaho Falls, ID 83404

    Site contact: 208-552-7700

  • Solaris Clinical Research

    Meridian, ID 83646

    Site contact: 208-288-0123

  • Great Lakes Clinical Trials - Ravenswood

    Chicago, IL 60640

    Site contact: 773-275-3500 Ext 162

  • Iowa Diabetes and Endocrinology Research Center

    West Des Moines, IA 50266

    Site contact: 515-329-6800

  • Pennington Biomedical Research Center

    Baton Rouge, LA 70808

    Site contact: 225-763-2578

  • IMA Clinical Research Monroe-Main

    Monroe, LA 71201

    Site contact: 318-737-1098

  • Centennial Medical Group

    Columbia, MD 21045

    Site contact: 443-698-8678

  • Brigham and Women's Hospital Diabetes Program

    Boston, MA 02115

    Site contact: 617-732-4245

  • Great Lakes Research Group, Inc.

    Bay City, MI 48706

    Site contact: 989-895-9100

  • Great Lakes Research Institute

    Southfield, MI 48075

    Site contact: David Strong

  • Headlands Research-Twin Cities

    Maplewood, MN 55109

    Site contact: Charlene McEvoy

  • Clinvest Headlands Llc

    Springfield, MO 65807

    Site contact: 417-883-7889

  • M3 Wake Research - Las Vegas Cimarron

    Las Vegas, NV 89113

    Site contact: 702-893-8968

  • Renascor Clinical Research

    Reno, NV 89509

    Site contact: 775-544-0376

  • IMA Clinical Research Warren

    Warren Township, NJ 07059

    Site contact: Nancy Phillips

  • Drug Trials America

    Hartsdale, NY 10530

    Site contact: 914-341-2346

  • Rochester Clinical Research, LLC

    Rochester, NY 14609

    Site contact: 585-288-0890

  • Medication Management

    Greensboro, NC 27401

    Site contact: 336-763-6968

  • West Clinical Research

    Morehead City, NC 28557

    Site contact: 252-515-0050

  • Trial Management Associates - Wilmington - Floral Parkway

    Wilmington, NC 28403

    Site contact: William Jones

  • Lillestol Research

    Fargo, ND 58104

    Site contact: 701-232-7705

  • Remington-Davis, Inc

    Columbus, OH 43215

    Site contact: 614-487-2560

  • Central States Research

    Tulsa, OK 74136

    Site contact: 918-645-5400

  • The Corvallis Clinic, P.C.

    Corvallis, OR 97330

    Site contact: Daniel Barrett

  • Clinical Renal Associates Ltd.

    Media, PA 19063

    Site contact: 610-872-8501

  • Suburban Research Associates

    West Chester, PA 19380

    Site contact: Omer Abdullah

  • Care Access - Mauldin

    Mauldin, SC 29662

    Site contact: 864-202-6290

  • New Phase Research and Development

    Knoxville, TN 37909

    Site contact: 865-200-8364

  • Clinical Research Associates Inc

    Nashville, TN 37203

    Site contact: 615-329-0197

  • IMA Clinical Research Austin

    Austin, TX 78745

    Site contact: Yu-Mei Liu

  • Headlands Horizons, LLC dba Headlands Research-Brownsville

    Brownsville, TX 78526

    Site contact: Christopher Romero

  • Cedar Health Research - Texas Native Health

    Dallas, TX 75235

    Site contact: 214-253-8170

  • Headlands Research-El Paso

    El Paso, TX 79902

    Site contact: 915-910-7088

+ 9 more on the official record.

Study contacts (from the official record)

  • Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · 317-615-4559 · LillyTrials@Lilly.com
  • Physicians interested in becoming principal investigators please contact · clinical_inquiry_hub@lilly.com
All weight loss studies in Alabama →
A Study of Orforglipron in Participants With Overweight at Risk of… (NCT07794579) | Bored Studies